Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adagrasib + cetuximab
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Adagrasib + cetuximab is a combination therapy consisting of adagrasib, an irreversible selective KRAS G12C inhibitor, and cetuximab, an anti-EGFR (epidermal growth factor receptor) antibody. This combination therapy targets KRAS G12C-mutated colorectal cancer, showing enhanced efficacy compared to adagrasib monotherapy. The combination works by inhibiting the KRAS G12C mutation while simultaneously blocking EGFR signaling, providing a dual mechanism to suppress cancer cell growth and proliferation.
- Brand names
- KRAZATI + cetuximabKRAZATI + Erbitux
02
Targets
EGFR (Epidermal growth factor receptor)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on adagrasib + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adagrasib + cetuximab.